Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8516792 | 0.80 | GABBR2 (0.56) | MMEACEGABBR2GABBR1MAPT | |
| SCHEMBL27497278 | 0.76 | ITGB3 (0.41) | MMEACEGABBR2GABBR1MAPT | |
| SCHEMBL28158048 | 0.74 | GABBR2 (0.38) | ALOX5GABBR2GABBR1CHRNB2CHRNB4 | |
| SCHEMBL5199435 | 0.73 | FFAR1 (0.47) | ALOX5MMECHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2039432 | 0.72 | CNR1 (0.43) | ALOX5GABBR2GABBR1LMNACYP3A4 | |
| SCHEMBL27516185 | 0.71 | CTSA (0.46) | GABBR2GABBR1 | |
| SCHEMBL3897980 | 0.71 | ALOX5 (0.45) | ALOX5GABBR2GABBR1CHRNB2CHRNB4 | |
| SCHEMBL4450623 | 0.71 | ALOX5 (0.41) | ALOX5GABBR2GABBR1CHRNB2CHRNB4 | |
| SCHEMBL4450617 | 0.71 | ALOX5 (0.41) | ALOX5GABBR2GABBR1CHRNB2CHRNB4 | |
| SCHEMBL29110953 | 0.70 | ALOX5 (0.41) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247608-B2 | Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors | PHARMALEADS (FR) | 2012-08-21 | — | — | US | disclosed |
| US-8247609-B2 | Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors | Pharamleads (FR) | 2012-08-21 | — | — | US | disclosed |
| US-20090131509-A1 | Aminoacid Derivatives Containing a Disulfanyl Group in the form of Mixed Disulfanyl and Aminopeptidase N Inhibitors | PHARMALEADS (FR) | 2009-05-21 | — | — | US | disclosed |
| US-20090012153-A1 | AMINOACID DERIVATIVES CONTAINING A DISULFANYL GROUP IN THE FORM OF MIXED DISULFANYL AND AMINOPEPTIDASE N INHIBITORS | PHARMALEADS (FR) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131509-A1 | Aminoacid Derivatives Containing a Disulfanyl Group in the form of Mixed Disulfanyl and Aminopeptidase N Inhibitors | HRH4, OPRL1, CNR2 | ALOX5 1221/4885MME 187/4885ACE 512/4885 |
| US-20090012153-A1 | AMINOACID DERIVATIVES CONTAINING A DISULFANYL GROUP IN THE FORM OF MIXED DISULFANYL AND AMINOPEPTIDASE N INHIBITORS | HRH4, CNR2, OPRM1 | ALOX5 1180/4885MME 247/4885ACE 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.